Fig. 4: Optimal dose for tumor-killing activity depends on patient-specific and time-dependent factors. | npj Systems Biology and Applications

Fig. 4: Optimal dose for tumor-killing activity depends on patient-specific and time-dependent factors.

From: Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma

Fig. 4

a The proportion of trimers, or a trimer:BCMA ratio, is plotted against the average BsAb concentration for 4 VPs, with each dose colored by response (red dot: no response, blue dot: biochemical response). A higher proportion of trimer suggests more antitumor activity based on the bell-shaped dose-response theory for BsAbs. VPs 9, 13, and 14 were objective biochemical responders and showed a peak of antitumor activity for lower doses, and a bell-shaped curve is evident for VPs 9 and 14. For these 3 patients, a higher BsAb concentration, a consequence from either a higher dose or lack of dose reduction, could result in inferior efficacy. VP 22, which was a nonresponder at all doses, has a monotonically increasing response curve, suggesting that an optimal dose was not seen within the range of doses simulated. All shown patients have a BL sBCMA < 100 ng/mL for simplicity. b sBCMA and c T cells in bone marrow were the most significant predictors for dose response curve shape, suggesting that patients with higher counts of these variables would benefit of higher dosing or drug exposure to improve antitumor efficacy. BsAb, bispecific antibody; QW, once weekly; sBCMA, soluble B-cell maturation antigen; VP, virtual patient.

Back to article page